Suppression of metastatic potential and up-regulation of gelatinases and uPA in LLC by protracted in vivo treatment with dacarbazine or razoxane

International Journal of Cancer

Volumn 72, Issue 6, 1997, Pages 1056-1061

  Garbisa, Spiridione ^a,d   Onisto, Maurizio ^a   Peron, Antonella ^a   Perissin, Laura ^b   Rapozzi, Valentina ^b   Zorzet, Sonia ^c   Giraldi, Tullio ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d Istituto di Istologia ed Embriologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; GELATINASE; GELATINASE A; GELATINASE B; MESSENGER RNA; RAZOXANE; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; IMMUNOCOMPETENCE; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG CARCINOMA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; COLLAGENASES; DACARBAZINE; GELATINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOSUPPRESSION; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; RAZOXANE; RNA, MESSENGER; TRANSCRIPTION, GENETIC; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030879815     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970917)72:6<1056::AID-IJC21>3.0.CO;2-1     Document Type: Article

References (31)

1. BELIN, D., VASSALLI, J.-D., COMBEPINE, C., GODEAU, F., NAGAMINE, Y., REICH, E., KOCHER, H.P. and DUVOSIN, R.M., Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur. J. Biochem., 148, 225-232 (1985).
2. BERETTA, G., BONADONNA, G., BAJETTA, E., TANCINI, G., DE LENA, M., AZZARELLI, A. and VERONESI, U., Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft-tissue sarcoma and Hodgkin's disease. Cancer Treat. Rep., 60, 205-211 (1976).
3. BOGGUST, W.A. and MCGAULEY, H., Inhibition of collagen peptidase in HeLa cells and human tumours by compounds including drugs used in cancer therapy. Brit. J. Cancer, 38, 329-334 (1978).
4. BONMASSAR, E., BONMASSAR, A., VADLAMUDI, S. and GOLDIN, A., Immunological alteration of leukemic cells in vivo after treatment with an anti-tumor drug. Proc. nat. Acad. Sci. (Wash.), 66, 1089-1095 (1970).
5. BONMASSAR, E., BONMASSAR, A., VADLAMUDI, S. and GOLDIN, A., Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide. Cancer Res., 32, 1446-1450 (1972).
6. BROOKS, P.C., STROMBLAD, S., SANDERS, L.C., VON SCHALSCHA, T.L., AIMES, R.T., STETLER-STEVENSON, W.G., QUIGLEY, J.P. and CHERESH, D.A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αVβ3. Cell. 85, 683-693 (1996).
7. BROWN, P.D., BLOXIDGE, R.E., STUART, N.S., GATTER, K.C. and CARMICHAEL, J., Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J. nat. Cancer Inst., 85, 574-578 (1993).
8. GANESH, S., SIER, C.F., HEERDING, M.M., VAN KRIEKEN, J.H., GRIFFIOEN, G., WELVAART, K., VAN DE VELDE, C.J., VERHEIJEN, J.H., LAMERS, C.B. and VERSPAGET, H.W., Prognostic value of the plasminogen-activation system in patients with gastric carcinoma. Cancer, 77, 1035-1043 (1996).
9. GARBISA, S., Correlation of MMP-2 with metastases. Bull. Inst. Pasteur, 92, 294-298 (1994).
10. GIRALDI, T., PERISSIN, L., ZORZET, S. and RAPOZZI, V., Anti-metastatic action of triazene derivatives. In: T. Giraldi, T.A. Connors and G. Cartei (eds.), Triazenes: chemical, biological and clinical aspects, pp. 45-62, Plenum, New York (1990).
11. GIRALDI, T., SAVA, G., CHERUBINO, R., BOTTIROLI, G. and MAZZINI, G., Effects of DTIC, DM-COOK and ICRF-159 on the number of circulating Lewis-lung-carcinoma cells detected by flow cytometry. Clin. exp. Metastasis, 2, 151-159 (1984).
12. GIRALDI, T., SAVA, G., CUMAN, R., NISI, C. and LASSIANI, L., Selectivity of the anti-metastatic and cytotoxic effects of 1-p-(3,3-dimethyl-1-triazeno(benzoic acid potassium salt, (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane, and cyclophosphamide in mice bearing Lewis lung carcinoma. Cancer Res., 41, 2524-2528 (1981).
13. HASUI, Y., MARUTSUKA, K., SUZUMIYA, J., KITADA, S., OSADA, Y. and SUMIYOSHI, A., The content of urokinase-type plasminogen-activator antigen as a prognostic factor in urinary bladder cancer. Int. J. Cancer, 50, 871-873 (1992).
14. HELLMANN, K., GILBERT, J., EVANS, M., CASSELL, P. and TAYLOR, R., Effect of razoxane on metastases from colorectal cancer. Clin. exp. Metastasis, 5, 1-8 (1987).
15. HERMANN, E.H., WITIAK, D.T., HELLMANN, K. and WARAVDEKAR, D.S., Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. In: S. Garattini, A. Goldin, F. Hawking and I.J. Kopin (eds.), Advances in pharmacology and chemotherapy, pp. 249-290. Academic Press, New York (1982).
16. LE SERVE, A.W. and HELLMANN, K., Metastases and the normalization of tumour blood vessels by ICRF-159: a new type of drug action. Brit. Med. J., 1, 597-601 (1972).
17. LIOTTA, L.A., STEEG, P.S. and STETLER-STEVENSON, W.G., Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336 (1991).
18. MAZZIERI, R., MASIERO, L., ZANETTA, L., MONEA, S., ONISTO, M., GARBISA, S. and MIGNATTI, P., Control of type-IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J., 16, 2319-2332 (1997).
19. MEER, L., JANZER, R.C., KLEIHUES, P. and KOLAR, G.F., In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem. Pharmacol., 35, 3243-3247 (1986).
20. MIGNATTI, P. and RIFKIN, D.B., Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73, 161-195 (1993).
21. NICOLINI, A., SPREAFICO, F., BONMASSAR, E. and GOLDIN, A., Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide in vivo. J. nat. Cancer Inst., 56, 89-93 (1976).
22. ONISTO, M., RICCIO, M.P., SCANNAPIECO, P., CAENAZZO, C., GRIGGIO, L., SPINA, M., STETLER-STEVENSON, W.G. and GARBISA, S., MMP-2/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int. J. Cancer, 63, 621-626 (1995).
23. PUCCETTI, P., ROMANI, L. and FIORETTI, M.C., Chemical xenogenization of tumour cells. Trends Pharmacol. Sci., 6, 485-487 (1985).
24. REPONEN, P., SAHLBERG, C., MUNAUT, C. THESLEFF, I. AND TRYGGVASON, K., High expression of 92-kDa type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J. cell Biol. 124, 1091-1102 (1994).
25. SAVA, G., CAPOZZI, I., BERGAMO, A., GAGLIARDI, R., COCCHIETTO, M., MASIERO, L., ONISTO, M., ALESSIO, E., MESTRONI, G. and GARBISA, S., Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. Int. J. Cancer, 68, 60-66 (1996).
26. SAVA, G., GIRALDI, T., LASSIANI, L. and NISI, C., Anti-metastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma. Cancer Res., 44, 64-68 (1984).
27. SLAVIK, M., Clinical studies with DTIC (NSC-45388) in various malignancies. Cancer Treat. Rep., 60, 213-214 (1976).
28. STETLER-STEVENSON, W.G., BROWN, P.D., ONISTO, M., LEVY, A.T. and LIOTTA, L.A., Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J. biol. Chem., 265, 13933-13938 (1990).
29. VENDITTI, J.M., Anti-tumour activity of DTIC (NSC-45388) in animals. Cancer Treat. Rep., 60, 135-140 (1976).
30. WITIAK, D.T., LEE, H.J., HART, R.W. and GIBSON, R.E., Study of transcyclopropylbis (diketopiperazine) and chelating agents related to ICRF 159. Cytotoxicity, mutagenicity, and effects on scheduled and unscheduled DNA synthesis. J. med. Chem., 20, 630-635 (1977).
31. ZORZET, S., PERISSIN, L., RAPOZZI, V., PACOR, S. and GIRALDI, T. Effects of prolonged treatment with dacarbazine on tumour metastatic potential in mice bearing Lewis lung carcinoma. Clin. exp. Metastasis, 13, 97-104 (1995).